Results 81 to 90 of about 12,593 (182)
Frontiers in Molecular Biosciences, 2020 BackgroundPirfenidone and nintedanib are the sole pharmacological therapies currently approved for idiopathic pulmonary fibrosis (IPF). Limited comparison data is available in literature, despite they are both prescribed for mild-to-moderate disease ...
Paolo Cameli +8 more
doaj +1 more source
Post‐Tuberculosis Lung Disease: Clinicopathologic Insights, Diagnosis, Prevention, and Management
MedComm, Volume 7, Issue 10, October 2026.A comprehensive review on post‐tuberculosis lung disease (PTLD) addresses the epidemiology, pathogenesis, clinical phenotypes and management, risk factors, prevention and systems approach, and future directions. This review provides standardized definitions, mechanistic insights and biomarkers of PTLD development, and clinical strategies for PTLD ...
Radha Gopalaswamy, Selvakumar Subbian
wiley +1 more source
Antifibrotic activities of pirfenidone in animal models [PDF]
, 2011 Pirfenidone is an orally active small molecule that has recently been evaluated in large clinical trials for the treatment of idiopathic pulmonary fibrosis, a fatal disease in which the uncontrolled deposition of extracellular matrix leads to progressive
C.J. Schaefer +4 more
core
, 2013 (B) Corneal re-epithelialization time: Corneal re-epithelialization time was significantly ...
Ruchit Trivedi (441693) +5 more
core +1 more source
Pirfenidone for the treatment of idiopathic pulmonary fibrosis [PDF]
, 2014 El pdf del artículo es la versión pre-print.[Introduction]: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and lethal fibrosing interstitial pneumonia.
Xaubet, Antoni +2 more
core +1 more source
MedComm, Volume 7, Issue 10, October 2026.The Hippo–YAP/TAZ–TEAD pathway integrates mechanical and biochemical cues to govern organ growth, regeneration, cancer, and fibrosis. This review dissects pathway physiology, TEAD structural pharmacology and ligandable pockets, and therapeutic strategies spanning palmitoylation‐pocket inhibitors, PROTAC degraders, and gene/RNA therapies, highlighting ...
Xiaodan Qu, Zhan‐you Wang
wiley +1 more source
BMC Pulmonary Medicine, 2012 Background Pirfenidone is a novel anti-fibrotic and anti-inflammatory agent that inhibits the progression of fibrosis in animal models and in patients with idiopathic pulmonary fibrosis (IPF).
Hisatomi Keiko +12 more
doaj +1 more source
MedComm, Volume 7, Issue 10, October 2026.Alveolar macrophages: development, respiratory homeostasis, signal pathways, diseases, and therapeutic opportunities: During embryonic development, fetal progenitors migrate to the developing lungs via a CX3CR1‐dependent mechanism to establish the TrAM pool.
Sihan Yang +4 more
wiley +1 more source
Contemporary Clinical Trials Communications, 2016 Idiopathic pulmonary fibrosis (IPF) is a rare, chronic and ultimately fatal disease for which only palliative treatments existed until recently. Between 2011 and 2015, two new drugs, pirfenidone and nintedanib, were approved in the US and Europe for the ...
Céline Audibert +2 more
doaj +1 more source
Radiotherapy‐Induced Side Effects: Epidemiology, Pathogenesis, Prevention and Treatments
MedComm, Volume 7, Issue 10, October 2026.Radiotherapy for malignancies frequently injures the organs’ systems through oxidative stress, fibrosis, inflammation, and vascular damage. This review systematically maps the epidemiology, pathogenesis, and emerging therapies to propose a mechanism‑network‑targeted framework for integrated, personalized care in radiation oncology.
Xiaowen Ma +9 more
wiley +1 more source